Medixo Centre

Ibrutinib can selectively kill malignant B cells by blocking the B cell receptor signaling pathway in cells. Ibrutinib has high bioavailability and good pharmacokinetic properties, and can quickly reach high blood concentrations after oral administration. It is widely distributed in various tissues throughout the body and can directly cross the blood-brain barrier, playing an important role in the treatment of malignant B cells in the central nervous system.